Sequential treatment for Alzheimer's disease
Part of Brain & nervous system, Mental health clinical trials.
This study tests a sequence of treatments to see if they can help people with Alzheimer's disease or mild cognitive impairment. It aims to slow down memory decline and improve daily function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 55 and 85 years old
- You or a family member have noticed memory problems for at least 6 months
- You have been diagnosed with mild cognitive impairment due to Alzheimer's or Alzheimer's dementia
- You are able to have memory tests, blood draws, and brain scans (MRI or PET)
- You are willing to follow the study schedule and give consent (or have a legal representative do so)
- You do not have other conditions like stroke, head injury, thyroid issues, or vitamin deficiencies that could cause memory loss
- You are not currently taking medications for memory that you haven't stopped at least 4 weeks before starting
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a gentle, non-invasive brain stimulation (transcranial alternating current) can improve memory and thinking in people with early Alzheimer's or mild memory problems. It involves regular sessions of stimulation and check-ups over several months.
This trial tests a new drug called CM383 in people with mild cognitive impairment or mild Alzheimer's disease. The goal is to see if it can help slow down memory loss.
This study enrolls people with no memory impairment, mild memory problems, or mild Alzheimer’s dementia to test how brain scans and cognitive tests relate to Alzheimer’s disease. It may help by contributing to better early diagnosis and by letting you see whether you fit into the study’s imaging and blood-test pathway.
This study tests an investigational drug called BEY2153 for people with early Alzheimer's disease (mild cognitive impairment or mild dementia). The goal is to see if it is safe and slows down memory decline.
This study tests an experimental drug for Alzheimer's called NTRX-07. It aims to see if it can slow memory decline for people with mild to moderate Alzheimer's.
This study follows adults 40+ to better understand and track changes in memory and thinking as people age. It groups people with normal thinking, subjective complaints, mild cognitive impairment, early Alzheimer’s, and vascular (blood vessel) related brain changes to find what predicts progression.
Hear when a new Mild Cognitive Impairment Due to Alzheimer Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.